爱科百发宣布爱司韦™在治疗呼吸道合胞病毒（RSV）感染的住院婴幼儿中的临床三期试验达到主要终点
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在临床三期AirFLO试验中，爱司韦™与安慰剂相比显著降低症状评分（p=0.002）及病毒载量（p=0.006），达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
March 25, 2022 08:00 ET
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
爱科百发宣布完成抗呼吸道合胞病毒新药齐瑞索韦的III期临床试验全部患者入组和用药治疗
January 25, 2022 05:06 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) --...
ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
January 25, 2022 05:06 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
January 07, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Appoints Dr. John Shiver to Board of Directors
January 05, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax to Participate in Upcoming Investor Conferences
November 11, 2021 16:22 ET
|
Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Point-of-Care Molecular Diagnostics Market Size ($5,381.18Mn by 2028) Lead by Assays and Kits (13.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 29, 2021 13:28 ET
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market: Key InsightsAccording to our new research study on Point-of-Care Molecular Diagnostics Market Size and...
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 13, 2021 16:05 ET
|
Icosavax, Inc.
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP...
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
September 10, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...